Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Ottawa, Aug. 26, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the global vehicle-to-grid technology market size accounted for USD 11.89 billion in 2026 and is estimated to grow from...
-
NEW DELHI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- TransFi has announced the launch of its stablecoin-native global payment infrastructure, designed to solve the inefficiencies of traditional...
-
Boulder, Aug. 23, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has...
-
BUFFALO, Wyo., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Crazy Woman Creek Bancorp, Inc. (OTCPK:CRZY) today announced a full redemption of its $2.0 million aggregate principal amount of fixed-to-floating...
-
New York, Aug. 16, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The content herein does not constitute medical, legal, or financial advice. Sonicsmooth Pro+ is not...
-
SINGAPORE, Aug. 15, 2025 (GLOBE NEWSWIRE) -- At a pivotal moment in the evolution of global financial technology, Orizon, an innovative protocol that fuses cutting-edge Artificial Intelligence...
-
From pro-level performance to creator-grade sound, the newest OMEN and HyperX lineup gives gamers more ways to play harder, stream better, and stay in control News Highlights: Delivers extreme...
-
14 August 2025 2025 Interim Results Highlights Admiral Group reports excellent H1 2025 results Six months ended: 30 June 202530 June 2024% change vs. 2024Group profit before tax from continuing...
-
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type...
-
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab...